JP6900385B2 - トリテルペンサポニン類似物 - Google Patents

トリテルペンサポニン類似物 Download PDF

Info

Publication number
JP6900385B2
JP6900385B2 JP2018543061A JP2018543061A JP6900385B2 JP 6900385 B2 JP6900385 B2 JP 6900385B2 JP 2018543061 A JP2018543061 A JP 2018543061A JP 2018543061 A JP2018543061 A JP 2018543061A JP 6900385 B2 JP6900385 B2 JP 6900385B2
Authority
JP
Japan
Prior art keywords
group
oxygen
nitrogen
antigen
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018543061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537527A (ja
Inventor
ジン・デービット・ワイ
チア・エリック
フェルナンデス−テハダ・アルベルト
ガードナー・ジェフリー
ルイス・ジェイソン
リヴィングストン・フィリップ
マーティン・ジェイ・タイラー
ノードストローム・ラース
ピラーセッティ・ナガ・バラ・キショレ
ラグパティ・ゴーヴィンド
タン・ディレック
Original Assignee
アジュバンス・テクノロジーズ・インコーポレーテッド
メモリアル スローン ケタリング キャンサー センター
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジュバンス・テクノロジーズ・インコーポレーテッド, メモリアル スローン ケタリング キャンサー センター, メモリアル スローン ケタリング キャンサー センター filed Critical アジュバンス・テクノロジーズ・インコーポレーテッド
Publication of JP2018537527A publication Critical patent/JP2018537527A/ja
Priority to JP2021099839A priority Critical patent/JP2021152043A/ja
Application granted granted Critical
Publication of JP6900385B2 publication Critical patent/JP6900385B2/ja
Priority to JP2022176130A priority patent/JP2023012519A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
JP2018543061A 2015-11-06 2016-11-04 トリテルペンサポニン類似物 Active JP6900385B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021099839A JP2021152043A (ja) 2015-11-06 2021-06-16 トリテルペンサポニン類似物
JP2022176130A JP2023012519A (ja) 2015-11-06 2022-11-02 トリテルペンサポニン類似物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562252296P 2015-11-06 2015-11-06
US62/252,296 2015-11-06
US201562268837P 2015-12-17 2015-12-17
US62/268,837 2015-12-17
PCT/US2016/060564 WO2017079582A1 (en) 2015-11-06 2016-11-04 Triterpene saponin analogues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021099839A Division JP2021152043A (ja) 2015-11-06 2021-06-16 トリテルペンサポニン類似物

Publications (2)

Publication Number Publication Date
JP2018537527A JP2018537527A (ja) 2018-12-20
JP6900385B2 true JP6900385B2 (ja) 2021-07-07

Family

ID=58662549

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018543061A Active JP6900385B2 (ja) 2015-11-06 2016-11-04 トリテルペンサポニン類似物
JP2021099839A Pending JP2021152043A (ja) 2015-11-06 2021-06-16 トリテルペンサポニン類似物
JP2022176130A Pending JP2023012519A (ja) 2015-11-06 2022-11-02 トリテルペンサポニン類似物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021099839A Pending JP2021152043A (ja) 2015-11-06 2021-06-16 トリテルペンサポニン類似物
JP2022176130A Pending JP2023012519A (ja) 2015-11-06 2022-11-02 トリテルペンサポニン類似物

Country Status (12)

Country Link
US (5) US20180327436A1 (https=)
EP (2) EP4001290A1 (https=)
JP (3) JP6900385B2 (https=)
KR (1) KR20180077180A (https=)
CN (2) CN112812143A (https=)
AU (1) AU2016349693B2 (https=)
CA (1) CA3003483C (https=)
CL (1) CL2018001192A1 (https=)
IL (3) IL286493B (https=)
SG (2) SG10202012205XA (https=)
WO (1) WO2017079582A1 (https=)
ZA (1) ZA201802891B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020517686A (ja) * 2017-04-25 2020-06-18 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
JP2022191284A (ja) * 2017-04-25 2022-12-27 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
JP2023012519A (ja) * 2015-11-06 2023-01-25 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112028951A (zh) * 2014-05-30 2020-12-04 索隆-基特林癌症研究协会 微小皂苷类似物、合成及其用途
EP3609505A4 (en) * 2017-04-13 2021-04-28 Adjuvance Technologies, Inc. TRITERPEN-SAPONIN SYNTHESIS, INTERMEDIATES AND COMBINATIONS OF ADJUVANCES
WO2019079160A1 (en) 2017-10-16 2019-04-25 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGS
US20230128815A1 (en) * 2020-03-23 2023-04-27 Adjuvance Technologies, Inc. Adjuvant compounds, salt forms, and formulations
WO2021236809A2 (en) 2020-05-19 2021-11-25 Othair Prothena Limited Multi-epitope vaccine for the treatment of alzheimer's disease
KR20230080397A (ko) 2020-08-07 2023-06-07 오타이르 프로테나 리미티드 알츠하이머 질환을 치료하기 위한 멀티에피토프 백신
WO2023056089A1 (en) 2021-10-03 2023-04-06 Eisai R&D Management Co., Ltd. Immunological adjuvant formulations comprising tlr4 agonist e6020
US20250025550A1 (en) * 2021-11-08 2025-01-23 Adjuvance Technologies, Inc. Adjuvant compounds and formulations
EP4190359A1 (en) 2021-12-03 2023-06-07 Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE Saponin-based adjuvants and vaccines
WO2023139145A1 (en) 2022-01-19 2023-07-27 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Saponin-based adjuvants and vaccines
CN117106004A (zh) * 2022-05-17 2023-11-24 北京科兴中维生物技术有限公司 三萜皂苷化合物及其制备方法及应用
WO2024218268A1 (en) 2023-04-20 2024-10-24 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Saponin derivatives as adjuvants and photoaffinity probes
WO2024261351A2 (en) 2024-05-08 2024-12-26 Vaccine Formulation Institute Ch Ltd. Immunologically active saponin fractions and adjuvant formulations

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (https=) 1974-03-12 1978-11-01
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US5215680A (en) 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
AU687355B2 (en) 1992-07-17 1998-02-26 Merck Sharp & Dohme Corp. Method for preventing zoster or alleviating varicella related post-herpetic neuralgia
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2263455C (en) 1996-08-23 2002-10-29 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
SK283760B6 (sk) 1996-10-15 2004-01-08 The Liposome Company, Inc. Farmaceutický prostriedok na dopravu bioaktívnych látok
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
WO2000009075A2 (en) * 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
AU7085400A (en) 1999-09-02 2001-03-26 Antigenics, Inc. Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
GB0401239D0 (en) 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
BRPI0811228A2 (pt) 2007-05-24 2014-10-21 Glaxonsmithkline Biolog S A Composição liofilizada, e, métodos para produzir uma composição liofilizada e para produzir uma composição imunológica.
CA2708716A1 (en) 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccines for malaria
JP5706815B2 (ja) 2008-04-08 2015-04-22 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ トリテルペンであるサポニン、その合成法および使用
SI2271360T1 (sl) 2008-04-16 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
AU2012255132B2 (en) 2011-05-17 2017-05-25 Soligenix, Inc. Thermostable vaccine compositions and methods of preparing same
WO2012156391A1 (en) 2011-05-17 2012-11-22 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
US20150037374A1 (en) 2013-07-31 2015-02-05 Csl Limited Anti-tumor compositions and uses thereof
CN112028951A (zh) * 2014-05-30 2020-12-04 索隆-基特林癌症研究协会 微小皂苷类似物、合成及其用途
WO2016096968A1 (en) 2014-12-18 2016-06-23 Glaxosmithkline Biologicals S.A. Vaccination
CA3003483C (en) 2015-11-06 2022-09-13 Adjuvance Technologies, Inc. Triterpene saponin analogues
US11629162B2 (en) 2015-12-17 2023-04-18 Memorial Sloan-Kettering Cancer Center Triterpene saponin variants, methods of synthesis and use thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
EP3609505A4 (en) 2017-04-13 2021-04-28 Adjuvance Technologies, Inc. TRITERPEN-SAPONIN SYNTHESIS, INTERMEDIATES AND COMBINATIONS OF ADJUVANCES
CN110730666A (zh) 2017-04-25 2020-01-24 佐剂技术公司 三萜皂苷类似物
EP3618836A4 (en) 2017-04-25 2021-01-13 Adjuvance Technologies, Inc. TRITERPENSAPONINALOGA
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
WO2019079160A1 (en) 2017-10-16 2019-04-25 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGS
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
CA3157372A1 (en) 2019-11-05 2021-05-14 Adjuvance Technologies, Inc. Varicella zoster

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023012519A (ja) * 2015-11-06 2023-01-25 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
JP2020517686A (ja) * 2017-04-25 2020-06-18 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
JP7177082B2 (ja) 2017-04-25 2022-11-22 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
JP2022191284A (ja) * 2017-04-25 2022-12-27 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物

Also Published As

Publication number Publication date
US20240327443A1 (en) 2024-10-03
US20180327436A1 (en) 2018-11-15
ZA201802891B (en) 2020-01-29
US10906926B2 (en) 2021-02-02
IL293848B2 (en) 2025-02-01
CN108778289A (zh) 2018-11-09
US12037355B2 (en) 2024-07-16
EP3370730A1 (en) 2018-09-12
JP2021152043A (ja) 2021-09-30
AU2016349693B2 (en) 2022-08-11
IL293848A (en) 2022-08-01
CL2018001192A1 (es) 2018-11-23
KR20180077180A (ko) 2018-07-06
IL259145B (en) 2021-09-30
CN112812143A (zh) 2021-05-18
IL286493B (en) 2022-07-01
CA3003483A1 (en) 2017-05-11
SG10202012205XA (en) 2021-01-28
CA3003483C (en) 2022-09-13
EP3370730A4 (en) 2019-07-31
US20200239509A1 (en) 2020-07-30
CN108778289B (zh) 2020-11-17
IL293848B1 (en) 2024-10-01
EP4001290A1 (en) 2022-05-25
JP2018537527A (ja) 2018-12-20
IL286493A (en) 2021-10-31
SG11201803594TA (en) 2018-05-30
AU2016349693A1 (en) 2018-05-17
US20210002316A1 (en) 2021-01-07
JP2023012519A (ja) 2023-01-25
US20230219991A1 (en) 2023-07-13
IL259145A (en) 2018-06-28
WO2017079582A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
JP6900385B2 (ja) トリテルペンサポニン類似物
JP2021152043A5 (https=)
JP7177082B2 (ja) トリテルペンサポニン類似物
KR102453184B1 (ko) 트리테르펜 사포닌, 그의 합성 방법, 및 그의 용도
JP2022191284A (ja) トリテルペンサポニン類似物
US20230357300A1 (en) Triterpene saponin synthesis, intermediates and adjuvant combinations
US20260115281A1 (en) Triterpene saponin analogues
HK40042493A (en) Triterpene saponin analogues
HK40016648A (en) Triterpene saponin analogues
HK1260769A1 (en) Triterpene saponin analogues
HK1260769B (en) Triterpene saponin analogues
HK40016652A (zh) 三萜皂苷类似物

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210519

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210616

R150 Certificate of patent or registration of utility model

Ref document number: 6900385

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250